| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| Targets |
IC50: LXR[1]
|
|---|---|
| ln Vitro |
DMHCA (10 µM; 16–18 hours) treats diabetes CD34+ cells ex vivo and returns membrane fluidity to pre-diabetic levels[1]. When compared to control mice, DMHCA markedly reduces CCL-2 generation by >50% in the BM supernatants and the systemic circulation while restoring baseline levels of BM-derived TNF-α and IL-3. Additionally, DMHCA upregulates the egression of vascular reparative cells into the peripheral circulation and increases the amount of CACs in the BM and peripheral circulation [1]. According to the PAGA analysis, erythrocyte progenitor robustness and overall production are improved by DMHCA treatment. Flux down the erythrocyte progenitor lineage is improved by DMHCA. Moreover, it DMHCA raises the density of erythrocyte progenitor cells in bone marrow. DMHCA raises the expression of the hemoglobin beta adult chain (HBB-BT) in addition to increasing the fraction of erythrocyte progenitors[1].
|
| ln Vivo |
In diabetic retinal patients, DMHCA (oral dosage; 6 months; meal 8 mg/kg body weight /day) restores cholesterol homeostasis. In the diabetic retina, it markedly raises total oxysterol, desmosterol, and endogenous LXR ligands[1].
|
| References |
| Molecular Formula |
C26H43NO2
|
|---|---|
| Molecular Weight |
401.63
|
| Exact Mass |
401.329
|
| CAS # |
79066-03-8
|
| PubChem CID |
24768125
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.43
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
29
|
| Complexity |
670
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C
|
| InChi Key |
NDGUBXOBXSPVHJ-LXVLQKCJSA-N
|
| InChi Code |
InChI=1S/C26H43NO2/c1-17(6-11-24(29)27(4)5)21-9-10-22-20-8-7-18-16-19(28)12-14-25(18,2)23(20)13-15-26(21,22)3/h7,17,19-23,28H,6,8-16H2,1-5H3/t17-,19+,20+,21-,22+,23+,25+,26-/m1/s1
|
| Chemical Name |
(4R)-4-[(3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-N,N-dimethylpentanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 7.69 mg/mL (19.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.77 mg/mL (1.92 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 7.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 0.77 mg/mL (1.92 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 7.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4899 mL | 12.4493 mL | 24.8985 mL | |
| 5 mM | 0.4980 mL | 2.4899 mL | 4.9797 mL | |
| 10 mM | 0.2490 mL | 1.2449 mL | 2.4899 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
